William Blair Issues Pessimistic Forecast for JANX Earnings

Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) - Equities researchers at William Blair cut their FY2024 earnings per share estimates for shares of Janux Therapeutics in a research note issued to investors on Wednesday, November 6th. William Blair analyst M. Phipps now expects that the company will post earnings of ($1.28) per share for the year, down from their previous estimate of ($0.94). The consensus estimate for Janux Therapeutics' current full-year earnings is ($1.29) per share. William Blair also issued estimates for Janux Therapeutics' Q4 2024 earnings at ($0.35) EPS, Q1 2025 earnings at ($0.35) EPS, Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.37) EPS, FY2025 earnings at ($1.45) EPS, FY2026 earnings at ($1.74) EPS and FY2027 earnings at ($2.84) EPS.

Other research analysts have also issued research reports about the company. Scotiabank lowered their price target on Janux Therapeutics from $47.00 to $42.00 and set a "sector perform" rating on the stock in a research report on Friday, August 9th. HC Wainwright reissued a "buy" rating and set a $63.00 target price on shares of Janux Therapeutics in a report on Thursday. Cantor Fitzgerald reissued an "overweight" rating and set a $100.00 target price on shares of Janux Therapeutics in a report on Thursday. UBS Group assumed coverage on Janux Therapeutics in a report on Thursday, October 24th. They set a "buy" rating and a $69.00 target price on the stock. Finally, Wedbush reissued an "outperform" rating and set a $74.00 target price on shares of Janux Therapeutics in a report on Thursday, August 8th. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $66.44.

Janux Therapeutics Trading Down 0.4 %

Shares of NASDAQ:JANX traded down $0.24 during trading on Monday, hitting $53.68. 1,011,505 shares of the company were exchanged, compared to its average volume of 715,061. The stock has a market cap of $2.82 billion, a price-to-earnings ratio of -44.62 and a beta of 3.52. Janux Therapeutics has a fifty-two week low of $5.80 and a fifty-two week high of $65.60. The firm has a fifty day moving average price of $49.02 and a two-hundred day moving average price of $46.35.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.18). The company had revenue of $0.44 million for the quarter, compared to analyst estimates of $1.50 million. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The firm's revenue for the quarter was down 82.6% on a year-over-year basis.

Hedge Funds Weigh In On Janux Therapeutics

A number of hedge funds have recently made changes to their positions in JANX. Summit Securities Group LLC bought a new stake in Janux Therapeutics in the second quarter worth approximately $29,000. Amalgamated Bank increased its holdings in Janux Therapeutics by 61.1% in the second quarter. Amalgamated Bank now owns 970 shares of the company's stock worth $41,000 after purchasing an additional 368 shares in the last quarter. Plato Investment Management Ltd bought a new stake in Janux Therapeutics in the second quarter worth approximately $42,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Janux Therapeutics by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company's stock valued at $87,000 after acquiring an additional 339 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Janux Therapeutics during the second quarter valued at approximately $151,000. 75.39% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, major shareholder Ventures Xi L.P. Avalon sold 108,365 shares of the firm's stock in a transaction on Friday, September 6th. The stock was sold at an average price of $42.00, for a total value of $4,551,330.00. Following the transaction, the insider now owns 3,162,851 shares in the company, valued at approximately $132,839,742. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, CEO David Alan Campbell sold 25,000 shares of the firm's stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $53.54, for a total transaction of $1,338,500.00. Following the completion of the transaction, the chief executive officer now directly owns 282,054 shares in the company, valued at $15,101,171.16. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Ventures Xi L.P. Avalon sold 108,365 shares of the firm's stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $42.00, for a total value of $4,551,330.00. Following the transaction, the insider now owns 3,162,851 shares of the company's stock, valued at $132,839,742. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 420,610 shares of company stock worth $19,288,666. Company insiders own 29.40% of the company's stock.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.